Spotlight
Money Desk
Obituaries
Classifieds
Families First
News
Weather
Specialists
Sports
Business
Opinion
Consumer
Health
Life
Out & About
Login
Weather
7 NC counties are under alert, including Johnston County.
Program
Former President Obama headlining night 2 of the DNC. His strong endorsement of VP Harris and his hopes for November
Program
On WRAL at 6: Hidden fees in your childâs school lunch payment ð¨ð¸ 5 On Your Side shows you how to keep more money in your pocket
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
Dow Jones Industrial Average
Nasdaq Composite
Standard & Poors 500
Gold
Crude Oil
Local Stocks
WRALTechWire 30
WRALTechWire 30
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Alpine Immune Sciences Inc
(NQ:
ALPN
)
N/A
UNCHANGED
Last Price
Updated: 4:00 PM EDT, May 17, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
Headline News about Alpine Immune Sciences Inc
< Previous
1
2
3
4
Next >
What 11 Analyst Ratings Have To Say About Alpine Immune Sciences
May 16, 2024
Via
Benzinga
ALPN Stock Earnings: Alpine Immune Sciences Beats EPS, Beats Revenue for Q1 2024
May 09, 2024
ALPN stock results show that Alpine Immune Sciences beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024.
Via
InvestorPlace
3 Growth Stocks You’ll Kick Yourself for Not Buying Today
May 03, 2024
Netflix, Intuit, and Vertex Pharmaceuticals are three growth stocks to buy, each positioned for significant market share and returns.
Via
InvestorPlace
PTC Therapeutics Stock Sees IBD RS Rating Climb To 72
May 01, 2024
PTC Therapeutics stock saw a positive improvement to its Relative Strength (RS) Rating on Wednesday, rising from 61 to 72.
Via
Investor's Business Daily
Sarepta Therapeutics Stock Shows Improved Technical Strength
April 29, 2024
The Relative Strength (RS) Rating for Sarepta Therapeutics stock headed into a new percentile Monday, as it got a lift from 70 to 73.
Via
Investor's Business Daily
$100B Vertex Pharma Working To Recreate $10B Cystic Fibrosis Success - This Time Focused On Pain Management Drugs
April 26, 2024
Unlock Vertex Pharmaceuticals' pioneering treatments, from the groundbreaking Trikafta for cystic fibrosis to the promising non-opioid painkillers.
Via
Benzinga
Vertex Pharmaceuticals Just Made 2 Big Moves. Is the Stock a Buy?
April 23, 2024
Vertex is broadening its portfolio.
Via
The Motley Fool
Looking for Once-in-a-Generation Investment Opportunities? Here Are 3 Magnificent Stocks to Buy Right Now
April 22, 2024
These stocks could be near major inflection points.
Via
The Motley Fool
3 Relatively Safe Growth Stocks You Can Buy and Hold
April 20, 2024
Low risk and high-reward potential? These stocks could offer both.
Via
The Motley Fool
Does This Acquisition Make Vertex Pharmaceuticals Stock a Buy?
April 18, 2024
The biotech just added another potential growth driver to its pipeline.
Via
The Motley Fool
Can You Afford to Ignore These 3 Biotech Stocks Up Over 160% in 2024?
April 15, 2024
Discover three biotech stocks with explosive growth potential. Don't miss out on these great picks this year.
Via
InvestorPlace
Here's (at Least) 1 new Reason to Buy Vertex Pharmaceuticals Stock
April 15, 2024
Vertex just laid claim to an asset that might be very valuable.
Via
The Motley Fool
Could This Stock Be the Next Biotech Buyout?
April 13, 2024
Vertex Pharmaceuticals' $4.9 billion purchase of Alpine Immune Sciences probably won't be the last acquisition of a company focused on kidney disease.
Via
The Motley Fool
Stock Market Sends Mixed Signals; Nvidia, Inflation, Mideast Fears In Focus: Weekly Review
April 12, 2024
The stock market gave some bullish signs, with Nvidia rebounding, but the indexes generally fell for the week on inflation and Mideast fears.
Via
Investor's Business Daily
Topics
Economy
Exposures
Interest Rates
Stocks Surge, Goldgasms To Record High After "Adjusted" PPI Sparks Buying Frenzy
April 11, 2024
What started off as another ugly day with stocks tumbling and yields surging following yesterday's VaR-shock-inducing CPI print, quickly reversed after the market - in its infinite stupidity - took...
Via
Talk Markets
Vertex's Alpine Acquisition: Unpacking Analyst Predictions on Povetacicept's Potential Impact
April 11, 2024
Vertex Pharmaceuticals to acquire Alpine Immune Sciences for $4.9 billion, expanding into nephrology with promising APOL1-mediated kidney disease treatments. Analysts foresee significant revenue growth...
Via
Benzinga
Stocks Bounce Back With Tech, Gold Gaining After Modest Producer Inflation Data: What's Driving Markets Thursday?
April 11, 2024
Investors can breathe a sigh of relief on Thursday as last month’s Producer Price Index (PPI) inflation turned out slightly lower than expected, albeit with some caveats across different measures...
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Why Fastenal Shares Are Trading Lower By Around 7%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
April 11, 2024
Shares of Fastenal Company (NASDAQ: FAST) fell sharply during Thursday’s session following worse-than-expected first-quarter financial results.
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Intraday Session
April 11, 2024
Via
Benzinga
Enliven Therapeutics, Alpine Immune Sciences, Janux Therapeutics And Other Big Stocks Moving Higher On Thursday
April 11, 2024
U.S. stocks were mixed, with the Dow Jones index falling over 50 points on Thursday. Shares of Enliven Therapeutics, Inc. (NASDAQ: ELVN) rose sharply during Thursday’s session.
Via
Benzinga
Topics
Stocks
Exposures
US Equities
The $5 BILLION Reason Alpine Immune Sciences (ALPN) Stock Is Up 30% Today
April 11, 2024
Vertex hopes Alpine's drug can be tested on other conditions beyond the one entering Phase 3 trial for a kidney disease.
Via
InvestorPlace
Biotech Stocks Heat As Arvinas Scores Novartis Licensing Pact, Janux Reportedly Explores Options
April 11, 2024
Novartis snagged a licensing deal with Arvinas worth up to $1.16 billion, while Janux is said to be exploring its options.
Via
Investor's Business Daily
Vertex Pharmaceuticals Moves Beyond $10B Cystic Fibrosis Franchise, Pays Around $5B For Kidney Disease Player Alpine Immune
April 11, 2024
Vertex Pharmaceuticals to acquire Alpine Immune Sciences for $4.9 billion in cash. Povetacicept, a potent dual antagonist of BAFF and APRIL, shows promise in IgA nephropathy. Transaction expected to...
Via
Benzinga
12 Health Care Stocks Moving In Thursday's Pre-Market Session
April 11, 2024
Via
Benzinga
Wall Street Braces For Another Red Day Ahead Of More Inflation Data While Bitcoin Holds Above $70K: Analyst Sees Any Pullback As 'Phenomenal Buying Opportunity'
April 11, 2024
The negative mood on Wall Street may persist as investors await the release of another inflation report, which will have significant implications for the near-term trend in cons
Via
Benzinga
Topics
Economy
Exposures
Interest Rates
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday
April 11, 2024
We're starting off Thursday with a breakdown of all the biggest pre-market stock movers traders will want to keep an eye on this morning!
Via
InvestorPlace
Why Rallybio Shares Are Trading Higher By Around 78%; Here Are 20 Stocks Moving Premarket
April 11, 2024
Shares of Rallybio Corporation (NASDAQ: RLYB) rose sharply in today’s pre-market trading after the company announced a collaboration with Johnson & Johnson to advance therapeutics for pregnant...
Via
Benzinga
Why Bitcoin-Linked MicroStrategy Along With Adial Pharmaceuticals, Alpine Immune Sciences, Marin Software, And Tesla Are On Investors' Radars Today
April 10, 2024
On Wednesday, key U.S. stock indexes closed lower, as the Dow Jones Industrial Average fell by 1.1% to 38,461.51, the S&P 500 dropped nearly 1% to 5,160.64, and the Nasdaq ended the day down by 0.8% at...
Via
Benzinga
Topics
Stocks
Exposures
US Equities
Vertex Pharmaceuticals Nabs Alpine Immune Sciences In $4.9 Billion Deal
April 10, 2024
The companies expect the deal to close later this quarter.
Via
Investor's Business Daily
Why Is Kidney Disease-Focused Alpine Immune Sciences Stock Trading Higher On Wednesday?
April 10, 2024
Alpine Immune Sciences explores strategic options, potentially selling amid interest from buyers. The Seattle-based firm, with soaring stock up over 400%, evaluates various possibilities.
Via
Benzinga
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.